OUR MISSION
We aim to discover basic mechanisms that control gene expression and epigenetic reprogramming. We strive to apply this knowledge through manipulation of induced pluripotent stem (iPS) cells to model human disease and test potential therapies for personalized medicine.
Ongoing research in our group centers on disease modeling and drug screening using induced Pluripotent Stem (iPS) cells. Initially we used a novel EOS reporter vector to reprogram patient fibroblasts into iPS cells and more recently we perform CRISPR gene editing to create isogenic cell pairs. Next, Neural Progenitor Cells (NPC) are generated to produce neurons for defining phenotypes and expression patterns that are related to Rett syndrome (RTT) and autism spectrum disorder (ASD).
We also collaborate with the Mital lab to evaluate the cardiomyocyte phenotype of pediatric cardiomyopathies. Drug testing is then performed to rescue the patient-specific in vitro phenotypes. Overall, our goal is to utilize reprogramming technology to repurpose or identify novel drugs for personalized medicine.
Recent Publications
- Everolimus Rescues the Phenotype of Elastin Insufficiency in Patient Induced Pluripotent Stem Cell-Derived Vascular Smooth Muscle Cells. Kinnear C, et al., Arterioscler Thromb Vasc Biol. 2020 May; 40(5):1325-1339.
- Methylglyoxal couples metabolic and translational control of Notch signalling in mammalian neural stem cells. Rodrigues DC, et al., Nat Commun. 2020 Apr 24;11(1):2018
- Shifts in Ribosome Engagement Impact Key Gene Sets in Neurodevelopment and Ubiquitination in Rett Syndrome. Rodrigues DC, et al., Cell Reports. 2020 Mar 24; 30(12):4179-4196.
Synaptic Dysfunction in Human Neurons With Autism-Associated Deletions in PTCHD1-AS. Ross PJ, et al., Biological Psychiatry. 2020 Jan 15. (87):139-149.
SHANK2 mutations associated with autism spectrum disorder cause hyperconnectivity of human neurons. Zaslavsky K, et al., Nature Neuroscience. 2019 Apr;22(4):556-564.
